SCHEMBL1099596

SCHEMBL1099596

CC(C)c1c(NS(=O)(=O)c2ccc(C(=O)O)cc2)sc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.49
MMP12 P39900 2/20 0.43
MMP13 P45452 2/20 0.43
LIMK2 P53671 2/20 0.42
CA12 O43570 2/20 0.42
CA9 Q16790 2/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
POLB P06746 2/20 0.42
MAPT P10636 1/20 0.42
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
ALDH1A1 P00352 2/20 0.40
GFER P55789 2/20 0.40
STAT3 P40763 1/20 0.40
EP300 Q09472 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KIF11 P52732 1/20 0.40
CASP6 P55212 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1101435 0.88 PLAU (0.45) ACLYMEN1KMT2APOLBMAPT
SCHEMBL1098803 0.84 ACLY (0.52) ACLYCA12CA9MEN1KMT2A
SCHEMBL12469781 0.74 ACLY (0.76) ACLYKMT2AALDH1A1LMNAGAA
SCHEMBL1100192 0.72 CMA1 (0.53) ACLYMEN1KMT2AMAPTALDH1A1
SCHEMBL15199357 0.72 ACLY (0.62) ACLYCA12CA9MEN1KMT2A
SCHEMBL1098725 0.71 ACLY (0.51) ACLYCA12CA9MEN1KMT2A
SCHEMBL10299805 0.69 KEAP1 (0.56) ACLYCA12CA9MEN1KMT2A
SCHEMBL1100030 0.69 MCL1 (0.57) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL1099843 0.68 ACLY (0.54) ACLYCA12CA9MEN1KMT2A
SCHEMBL3715141 0.68 CA12 (0.75) CA12CA9MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 ACLY 1333/4885MMP12 3499/4885MMP13 4507/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 ACLY 1333/4885MMP12 3499/4885MMP13 4507/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 ACLY 1333/4885MMP12 3499/4885MMP13 4507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.